Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo7/14/2017 Back in March, Amgen’s Kyprolis posted new data showing it could top Takeda’s Velcade at extending survival. And now, the multiple myeloma-fighter has put up more survival results that will strengthen its case against its rivals... Subscribe to Read More...
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |